Overview
Hemas is a diversified Sri Lankan group spanning healthcare, consumer brands, mobility, leisure, travel, aviation, logistics and maritime services. Healthcare is the larger reported segment exposure, while Consumer Brands includes Atlas and other home and personal-care operations.
The latest reported quarter showed cost pressure at the operating level, contrasting with a prior audited year in which revenue and profit expanded. The central question is whether the group can protect margins while funding regional expansion.
Price performance
At LKR 31.80 on 5 November 2026, the share was down 8.9% over one year, compared with a 6.9% fall in the ASPI. It outperformed over six months, falling 3.0% against the index's 7.1% decline, so the longer-term lag is not uniform across the recent record.
The price sat 44.7% through its 52-week range. Sixty-day volatility was 38.5% below its own one-year level, while recent trading volume was broadly unchanged from the preceding 60-day norm.
The three-year record shows two falls of 15% or more, the deepest 24%, which took seven months to recover. Median daily turnover was about LKR 5.0 million: a LKR 1 million order is about 20% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
The market-wide measure places Hemas in the moderately undervalued band, with a score of 63 out of 100 based on price against filed book value, earnings and dividends. A P/E of 11.0 means the market price is LKR 11 for every LKR 1 of trailing profit, below the diversified-holdings median of 14.2.
A P/B of 1.71 means the price is LKR 1.71 for each LKR 1 of net assets, above the sector median of 1.17. That premium sits alongside a 15.5% trailing return on equity, but the own-history record is mixed: P/B is more expensive than 76% of days since January 2019, while P/E is cheaper than 63% of days since January 2019.
The 3.1% dividend yield exceeds the sector median, and the payout rose from LKR 0.90 in FY2025 to LKR 1.00 in FY2026. The latest June quarter supplied only 10.8% of trailing EPS; at its year-ago net margin, the same price would stand on 10.8 times earnings rather than 11.0 times.
News and sentiment
Company coverage was normal overall but unusually quiet in the latest month, with one article against a usual monthly baseline of 2.5. Of 19 material articles over 90 days, 10 were negative and eight positive, largely reflecting the June-quarter margin pressure alongside the earlier record annual result.
Hemas reported on 18 August that it acquired 75% of Kenya's Twiga Stationers and Printers for $16.2 million, creating its first overseas acquisition platform for Consumer Brands. The announcement does not disclose Twiga's revenue or earnings, so its contribution to group profit cannot yet be sized.
A LKR 0.25 first interim dividend has a confirmed ex-date of 16 November 2026 and payment date of 4 December 2026.
Financials
For the June 2026 quarter, revenue rose 0.9% year-on-year, but operating profit fell 21.1% and net profit fell 15.7%. Gross margin was 30.4% versus 30.1% a year earlier, operating margin was 5.7% versus 7.2%, and net margin was 3.7% versus 4.4%. The business retained slightly more gross profit per rupee of sales, but higher operating costs took a larger share before profit reached shareholders.
June has been Hemas's weakest quarter for operating margin on average over the five complete years on record. Against other June quarters, gross margin was among its best at second of seven, while operating and net margins were middling at fifth of seven, so the weak seasonal operating-margin position does not by itself establish a broader deterioration.
The LKR 569 million gap between operating and net profit was smaller than the LKR 809 million year earlier, but it did not offset the LKR 437 million operating-profit decline. At the latest audited year-end, net profit had grown 11.4%, showing that the June result followed a stronger annual base. The latest balance sheet and today's share count are both about 3.0 billion shares, so the reported per-share figures are on the current share base.
Risks
The main risk is margin pressure across a diversified operating base. The June operating margin fell to 5.7% from 7.2%, and the August results coverage attributed the earnings decline to cost escalation, distribution costs and rupee depreciation. Healthcare accounts for 62% of reported segment revenue, making procurement and regulatory conditions in that sector especially relevant to the group.
Balance-sheet risk is limited on the latest audited figures: gearing was 10.8%, interest cover was 13.79 times, and the current ratio was 1.72. In everyday terms, the group had LKR 1.72 of short-term assets, including inventory and customer receivables, for each LKR 1 due within a year. Cash conversion was 0.83 times, meaning operating cash flow was below operating profit, so not all reported operating profit arrived as cash.
The Kenya acquisition adds execution and foreign-market exposure, but the disclosed deal terms do not show the acquired business's earnings contribution. Inflation, fuel costs and rupee weakness are adverse operating conditions in the wider Sri Lankan backdrop, rather than company-specific events.
Outlook
As at 5 November 2026, the next interim filing for the quarter ended 30 September 2026 was due, with the usual filing window running from 2 to 14 November. It will show whether the June margin compression persisted beyond the group's historically weakest operating-margin quarter.
The confirmed 16 November dividend ex-date is the next corporate event. The available data cannot yet establish the profit contribution, integration costs or cash requirements of the Kenyan acquisition; subsequent filings are needed to show those effects.